Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afimoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 14/20 | 1.00 |
| ▸ | ESRRG known ✓ | P62508 | 8/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ESRRB | O95718 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | PLD1 | Q13393 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afimoxifene SCHEMBL9189 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL15668666 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL2132301 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL2165503 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL11899365 | 0.99 | ESR1 (0.97) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL9121934 | 0.97 | ESR1 (0.95) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649806 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649812 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL9857240 | 0.95 | ESR1 (0.90) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1127045-A2 | USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | AstraZeneca AB (SE) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025767-A2 | USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2000-05-11 | — | — | WO | claimed |
| US-5384260-A | EARLY DETECTION OF DEVELOPING TAMOXIFEN RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-01-24 | — | — | US | claimed |
| EP-0547141-A4 | — | — | 1994-01-05 | — | — | EP | claimed |
| EP-0547141-A1 | ONSET OF ANTIESTROGEN RESISTANCE IN BREAST CANCER | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-23 | — | — | EP | claimed |
| US-5119827-A | An increase in ratio of cis-4-hydroxy-tamoxifen to trans form causes treatment resistance | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-06-09 | — | — | US | claimed |
| WO-1992003973-A1 | ONSET OF ANTIESTROGEN RESISTANCE IN BREAST CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-03-19 | — | — | WO | claimed |
| US-4198435-A | Pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-15 | — | — | US | claimed |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2025-12-04 | — | — | US | disclosed |
| US-20250074959-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025024525-A1 | SYSTEMS AND METHODS FOR PREDICTING DRUG-INDUCED LIVER INJURY | CELLARITY, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12202897-B2 | Drug regulated transgene expression | SEATTLE CHILDREN'S HOSPITAL (US) | 2025-01-21 | — | — | US | disclosed |
| CN-118973608-A | System for drug-induced expression of polynucleotides | 美天施生物科技有限两合公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| EP-0002097-B1 | TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| EP-0011372-A1 | 1-Acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-05-28 | — | — | EP | disclosed |
| US-4198435-A | Pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
| US-4198435-A | Pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | CYP19A1, ESR1, ESR2 | ESR1 2/4885ESRRG 7/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.